SML2091
Dalcetrapib
≥97% (HPLC)
Synonym(s):
JTT-705, RO-4607381, S-[2-[[1-(2-ethylbutyl)cyclohexane]carbonylamino]phenyl]-2-methylpropanethioate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C23H35NO2S
CAS Number:
Molecular Weight:
389.59
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥97% (HPLC)
Form:
powder
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
CC(C)C(SC1=CC=CC=C1NC(C2(CCCCC2)CC(CC)CC)=O)=O
InChI
1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)
InChI key
YZQLWPMZQVHJED-UHFFFAOYSA-N
Biochem/physiol Actions
Cholesteryl ester transfer protein (CETP) inhibitor; increases serum levels of HDL-cholesterol
Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. It increases HDL levels, but showed variable results on clinical outcomes. Clinical outcomes, effects on C-reactive protein and cholesterol efflux have been found to be genotype-dependent, influenced by correlated polymorphisms in the ADCY9 (adenylate cyclase type 9) gene. Positive results were obtained with AA genotype of ADCY9 gene whereas the GG genotype showed negative results and the AG genotype was neutral.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jean-Claude Tardif et al.
Arteriosclerosis, thrombosis, and vascular biology, 37(3), 396-400 (2017-01-28)
High-density lipoproteins are involved in reverse cholesterol transport and possess anti-inflammatory and antioxidative properties. Paradoxically, CETP (cholesteryl ester transfer protein) inhibitors have been shown to increase inflammation as revealed by a raised plasma level of high-sensitivity C-reactive protein. CETP inhibitors
Marie-Jeanne Bertrand et al.
Expert opinion on emerging drugs, 22(1), 1-26 (2016-12-09)
Cardiovascular (CV) atherosclerotic disease remains the leading cause of morbidity and mortality worldwide, despite the advances in contemporary therapies. Inflammation is an important process in atherosclerosis, leading to plaque rupture and acute coronary syndrome. Although statin therapy has substantially reduced
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2091-25MG | 04061835502400 |
| SML2091-5MG | 04061835502417 |